Biosciences offer extraordinary value for patients, providers and payers. These complex products are the future of accessible medicine, which is why Amneal is working to further deepen our biosciences capabilities, starting with a broadening portfolio of biosimilar medications.
The Amneal Biosciences portfolio also includes a growing portfolio of complex, sterile, injectable products across multiple therapeutic areas.
Visit Amneal.com for the full line of Amneal products.
Amneal values strong partnerships with organizations that share our values and dedication. We are proud to partner with mAbxience to bring Alymsys (bevacizumab-maly) injection to the U.S market. Click here for a virtual tour of the facility where Alymsys is made.
Similarly, Amneal partnered with Kashiv BioSciences on the commercialization of both Releuko (filgrastim-ayow) and Fylnetra (pegfilgrastim-pbbk).